-+ 0.00%
-+ 0.00%
-+ 0.00%

PIERRE FABRE PHARMACEUTICALS RESUBMITS TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FOR TREATMENT OF EPSTEIN-BARR VIRUS POSITIVE-POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE TO THE FDA

Reuters·09/30/2026 12:00:51

Please log in to view news